Australia markets closed

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.8500-0.1000 (-3.39%)
At close: 1:00PM EST
2.8500 0.00 (0.00%)
After hours: 01:46PM EST
Currency in USD

Valuation measures

Market cap (intra-day) 544.00M
Enterprise value 341.02M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)9.03
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7-2.84

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-66.47%
S&P500 52-week change 326.87%
52-week high 318.5000
52-week low 31.7500
50-day moving average 32.6778
200-day moving average 35.9563

Share statistics

Avg vol (3-month) 3437.05k
Avg vol (10-day) 3102.13k
Shares outstanding 515.44M
Implied shares outstanding 6N/A
Float 810.04M
% held by insiders 132.32%
% held by institutions 122.28%
Shares short (14 Nov 2021) 4387.44k
Short ratio (14 Nov 2021) 40.45
Short % of float (14 Nov 2021) 43.37%
Short % of shares outstanding (14 Nov 2021) 42.51%
Shares short (prior month 14 Oct 2021) 441.21k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 June 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-180.54%
Return on equity (ttm)-425.08%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -14.57M
Net income avi to common (ttm)-14.88M
Diluted EPS (ttm)-2.2410
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.07M
Total cash per share (mrq)0.2
Total debt (mrq)91.6k
Total debt/equity (mrq)1.88
Current ratio (mrq)2.52
Book value per share (mrq)0.66

Cash flow statement

Operating cash flow (ttm)-9.87M
Levered free cash flow (ttm)-5.37M